There is a need for topical psoriasis treatments that in addition to being highly efficacious also are convenient and easy to use, as this could reduce the burden of daily treatment and improve adherence to therapy and real-life outcome.

The objective of this pooled post hoc analysis is to investigate the efficacy of calcipotriene (CAL)/betamethasone dipropionate (BDP) polyaphron dispersion (PAD)-cream in patients with moderate-to-severe psoriasis from two completed phase 3 studies conducted in the USA and Europe.

The proportion of patients achieving Physician Global Assessment treatment success as well as a modified Psoriasis Area and Severity Index (mPASI)75 response was higher in the subgroup with a body surface area > 10% and mPASI > 10 and Dermatology Life Quality Index > 10 at baseline compared to the overall patient population.

As indicated by this subgroup analysis, patients who had higher disease severity at baseline achieved greater efficacy than the total patient population when treated with 8 weeks of CAL/BDP PAD-cream as compared to a currently marketed active comparator.

CAL/BDP PAD-cream is a non-greasy, easy spreadable cream that is scored high in convenience even by patients with moderate-to-severe disease, which makes it an option for some patients with moderate-to-severe psoriasis either as monotherapy or as adjunctive therapy to systemic/biologic agents.